News – Page 993 – Endpoints News

Gilead locks in Daniel O'Day as CEO, tapping the Roche vet to rejuvenate growth

7 years ago

With fresh company building lessons from Ablynx, Edwin Moses is ready to try it again as chair of neoantigen biotech ...

7 years ago

Sanofi will eliminate 670 jobs in France; Moderna gets FDA orphan status for preclinical asset

7 years ago

Delay brings success for Roche as it finally wins FDA nod for Tecentriq regimen in frontline lung cancer

7 years ago

Bristol-Myers vet Caroline Loew heads up Glympse Bio; Kaleido nabs GSK's CMO Katharine Knobil

7 years ago

FDA will allow observational studies as part of a push for real world evidence, new framework says

7 years ago

Accused of milking the CMS with co-pay kickbacks, J&J's Actelion settles case for $310M

7 years ago

AstraZeneca's prized Imfinzi/tremelimumab combo fails again — this time in head and neck cancer

7 years ago

Moderna skirts the reefs of disaster and sails into Wall Street with a $604M IPO bounty — but shares slide

7 years ago

Mallinckrodt to spin off generics business; BeyondSpring ready to submit approval for lead drug in China

7 years ago

Joining hunt for hep B cure, Brii Bio inks maiden deals featuring VBI, Vir, WuXi with a big appetite for more

7 years ago

In search of biotech hub glory, the Big Apple lures local startups with lab space

7 years ago

Supernus touts ADHD Phase III data, but results appear to fall short of expectations

7 years ago

Disgraced VC Steven Burrill heads to prison with 30-month sentence for fraud, tax evasion

7 years ago

Seattle’s Impel NeuroPharma bags $67.5M crossover raise for a round of new drug/device CNS clinical trials

7 years ago

While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients

7 years ago

AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

7 years ago

Novartis’ partners at Conatus have another NASH setback to confess today

7 years ago

UK sets up vaccines centre as Brexit looms; Shanghai's Elpiscience bags $35M in Series B

7 years ago

Troubled MiMedx axes a quarter of its workforce in the wake of a C-suite purge

7 years ago

In the wake of deep R&D cuts, Bayer flags safety concerns for a top PhIII drug

7 years ago

Mereo reverse merges with a flailing OncoMed and preps for a back flip onto Nasdaq

7 years ago

Forget Hong Kong, Grail is now going for a 2019 IPO in the US — Bloomberg

7 years ago

A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames

7 years ago

First page Previous page 990 991 992993994 995 996 Next page Last page